Bifidobacterium bifidum G9‐1 Survives in the Intestinal Environment and Influences the Gut Microbiota Despite the Presence of Antimicrobials
Microbiology and Immunology · 2025
DOI: 10.1111/1348-0421.13230 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology and Immunology, 2025. Verfasst von Haruka Yokota und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biofermin Pharmaceutical Co. Ltd., Kobe, Japan. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Probiotics, Bifidobacterium bifidum, Anti-Bacterial Agents. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Probiotics can help prevent antibiotic‐associated diarrhea; however, those lacking antimicrobial resistance may be ineffective during antimicrobial treatment. Here, we aimed to examine the effects of antimicrobials on the probiotic strain Bifidobacterium bifidum G9‐1 (BBG9‐1). Minimum inhibitory concentrations were determined in vitro by culturing B. bifidum G9‐1 with antimicrobials and assessing its viability. For in vivo analysis, germ‐free and specific pathogen‐free mice were administered B. bifidum G9‐1 along with antimicrobials. Gut microbiota composition and viable B. bifidum G9‐1 abundance were determined. Bifidobacterium bifidum G9‐1 was highly sensitive to antimicrobials in vitro. However, in a complex bacterial environment mimicking the gut environment, the abundance of viable B. bifidum G9‐1 was significantly high despite antimicrobial exposure. Dominant bacterial populations were more affected by antimicrobials than nondominant populations, with B. bifidum G9‐1 exhibiting increased viability in the presence of diverse bacterial species. In vivo , combined administration of antimicrobials and B. bifidum G9‐1 significantly reduced B. bifidum G9‐1 abundance in germ‐free mice but not in specific pathogen‐free mice, where the gut microbiota composition shifted following administration of B. bifidum G9‐1. The presence of diverse live bacteria in the intestine promotes the survival of B. bifidum G9‐1 and its beneficial effects, even in the presence of antimicrobials. This finding suggests that B. bifidum G9‐1, despite lacking intrinsic antimicrobial resistance, can survive and reach the large intestine, maintaining its probiotic function. Therefore, B. bifidum G9‐1 can potentially be used for antibiotic‐associated diarrhea prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biofermin Pharmaceutical Co. Ltd., Kobe, Japan.
ORCID-Profile: Haruka Yokota, Yutaka Makizaki, Yoshiki Tanaka
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Yokota, H., Makizaki, Y., Tanaka, Y., & Ohno, H. (2025). Bifidobacterium bifidum G9‐1 Survives in the Intestinal Environment and Influences the Gut Microbiota Despite the Presence of Antimicrobials. Microbiology and Immunology. https://doi.org/10.1111/1348-0421.13230
Vancouver
Yokota H, Makizaki Y, Tanaka Y, Ohno H. Bifidobacterium bifidum G9‐1 Survives in the Intestinal Environment and Influences the Gut Microbiota Despite the Presence of Antimicrobials. Microbiology and Immunology. 2025. doi:10.1111/1348-0421.13230
BibTeX
@article{Yokota2025,
author = {Yokota, Haruka and Makizaki, Yutaka and Tanaka, Yoshiki and Ohno, Hiroshi},
title = {Bifidobacterium bifidum G9‐1 Survives in the Intestinal Environment and Influences the Gut Microbiota Despite the Presence of Antimicrobials},
journal = {Microbiology and Immunology},
year = {2025},
doi = {10.1111/1348-0421.13230}
}
EUVIMED